文献速递脊柱关节炎

TYK2/JAK1抑制剂Brepocitinib治疗活动性银屑病关节炎的疗效与安全性:IIb期随机对照试验

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2023-06-22

这项安慰剂对照、剂量递增的IIb期研究纳入218例中重度活动性银屑病关节炎患者,随机接受Brepocitinib 10mg、30mg或60mg每日一次或安慰剂治疗,第16周时30mg和60mg组ACR20应答率分别为66.7%和74.6%,均显著高于安慰剂组的43.3%,应答维持至第52周,不良事件多为轻中度。

要点

  • 第16周Brepocitinib 30mg和60mg组ACR20应答率分别为66.7%(P=0.0197)和74.6%(P=0.0006),安慰剂组为43.3%。
  • 30mg和60mg组ACR50/ACR70、PASI75/PASI90及MDA应答率均显著高于安慰剂组,疗效维持或改善至第52周。
  • 12例(5.5%)发生15起严重不良事件,其中6例(2.8%)为感染,均发生在30mg和60mg组,未发生主要不良心血管事件或死亡。

核心结论

  • Brepocitinib 30mg和60mg每日一次在改善银屑病关节炎症状和体征方面优于安慰剂,52周内总体耐受良好,安全性与其他Brepocitinib临床试验一致。

研究设计与样本

  • 这项安慰剂对照、剂量递增的IIb期研究纳入218例中重度活动性银屑病关节炎患者,随机接受Brepocitinib 10mg、30mg或60mg每日一次或安慰剂治疗,第16周后安慰剂组推进至30mg或60mg每日一次,评估至第52周。

主要发现

  • 第16周Brepocitinib 30mg组和60mg组ACR20应答率分别为66.7%(P=0.0197)和74.6%(P=0.0006),均显著高于安慰剂组的43.3%。
  • 第16周30mg和60mg组ACR50/ACR70、PASI75/PASI90及MDA应答率均显著高于安慰剂组,应答率维持或改善至第52周。
  • 不良事件多为轻中度,12例(5.5%)报告15起严重不良事件,其中6例(2.8%)为感染,均发生在30mg和60mg组;未发生主要不良心血管事件或死亡。

关键数值与推荐

  • 主要终点为第16周ACR20应答率,Brepocitinib 30mg组66.7%(P=0.0197)、60mg组74.6%(P=0.0006)对比安慰剂组43.3%。
  • 次要终点包括ACR50/ACR70、PASI75/PASI90和MDA应答率,30mg和60mg组均显著高于安慰剂组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Brepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in participants with moderately-to-severely active psoriatic arthritis (PsA) for up to 52 weeks. METHODS: In this placebo-controlled, dose-ranging, phase IIb study, participants were randomized to receive 10 mg, 30 mg, or 60 mg of brepocitinib once daily or placebo, advancing to 30 mg or 60 mg of brepocitinib once daily at week 16. The primary endpoint was the response rate according to the American College of Rheumatology criteria for 20% improvement (ACR20) in disease activity at week 16. Secondary endpoints included response rates according to the ACR50/ACR70 response criteria, 75% and 90% improvement in the Psoriasis Area and Severity Index (PASI75/PASI90) score, and minimal disease activity (MDA) at weeks 16 and 52. Adverse events were monitored throughout the study. RESULTS: Overall, 218 participants were randomized and treated. At week 16, the brepocitinib 30 mg and 60 mg once daily groups had significantly greater ACR20 response rates (66.7% [P = 0.0197] and 74.6% [P = 0.0006], respectively), versus the placebo group (43.3%), and significantly higher ACR50/ACR70, PASI75/PASI90, and MDA response rates. Response rates were maintained or improved through week 52. Adverse events were mostly mild/moderate; serious adverse events (15) in 12 participants (5.5%) included infections in 6 participants (2.8%) in the brepocitinib 30 mg and 60 mg once daily groups. No major adverse cardiovascular events or deaths occurred. CONCLUSION: Treatment with brepocitinib at dosages of 30 mg and 60 mg once daily was superior to placebo at reducing signs and symptoms of PsA. Brepocitinib was generally well tolerated throughout the 52-week study, with a safety profile consistent with those found in other brepocitinib clinical trials.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial. Arthritis Rheumatol. 2023. PMID: 37194394. doi:10.1002/art.42519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。